NCT05675410 2026-03-19
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
11 trialsNCT03907488 2025-12-04
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00000626 2021-10-27
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT00317408 2015-09-25
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase NA Unknown
NCT00003421 2013-12-04
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003262 2013-09-20
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00041210 2013-09-20
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00025064 2013-08-07
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00416377 2013-08-02
Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase NA Unknown
NCT00417014 2013-08-02
Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase NA Unknown
NCT00002714 2013-05-15
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease
National Cancer Institute (NCI)
Phase 2 Completed